New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

Table 1 Ongoing phase I/II studies testing PARP-inhibitors, immune checkpoint inhibitors and epigenetic drugs as monotherapy or in combinatorial regimen in advanced urothelial cancer

ClinicalTrials.gov identifier	Phase	Patients	PARP inhibitor	Checkpoint inhibitor	Epigenetic drug	References
NCT03448718	II	Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	Olaparib			N/A
NCT03375307	II	Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects	Olaparib			N/A
NCT03397394 (UCLA)	II	Locally Advanced or Metastatic Urothelial Carcinoma	Rucaparib			N/A
NCT02736266	II	Muscle-invasive Urothelial Bladder Carcinoma		Pembrolizumab		N/A
NCT02951767 (IMvigor 210)	II	Locally Advanced or Metastatic Urothelial Bladder Cancer		Atezolizumab		36
NCT02108652 (IMvigor 211)	II	Locally Advanced or Metastatic Urothelial Bladder Cancer		Atezolizumab		79
NCT02546661 (BISCAY)	Ib	Muscle Invasive Bladder Cancer	Olaparib	Durvalumab		N/A
NCT03534492 (NEODURVARIB)	II	Prior to Surgery of Resectable Urothelial Bladder Cancer	Olaparib	Durvalumab		N/A
NCT03459846 (BAYOU)	II	Advanced, Platinum-Ineligible Bladder Cancer	Olaparib	Durvalumab		N/A
NCT02619253	I	Advanced renal or urothelial cell carcinoma		Pembrolizumab	Vorinostat	N/A
NCT03179943	II	Advanced, Platinum-Ineligible Bladder Cancer		Atezolizumab	Guadecitabine	N/A

ISSN: 1756-9966